{"transactions":[{"id":1119914,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":36755,"kind":"person","name":"Smith David V","position":1,"cik":"0001229447","reported_name":"Smith David V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:27:46.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002034/form4.xml","form_type":"4"}},{"id":1119911,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":39978,"kind":"person","name":"Hunter Heidi","position":1,"cik":"0001891841","reported_name":"Hunter Heidi","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:27:20.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002033/form4.xml","form_type":"4"}},{"id":1119910,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:26:55.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002032/form4.xml","form_type":"4"}},{"id":1119909,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78796,"kind":"person","name":"Glaub Kathleen Sereda","position":1,"cik":"0001619612","reported_name":"Glaub Kathleen Sereda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:26:18.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002031","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002031/form4.xml","form_type":"4"}},{"id":1119908,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:25:55.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002030/form4.xml","form_type":"4"}},{"id":1119907,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:24:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002029/form4.xml","form_type":"4"}},{"id":1127836,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":39978,"kind":"person","name":"Hunter Heidi","position":1,"cik":"0001891841","reported_name":"Hunter Heidi","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-02T11:53:36.000Z","date":"2025-05-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.3923,"value":20884.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades in prices ranging from $1.37 to $1.40, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000905148-25-001960","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825001960/form4.xml","form_type":"4"}},{"id":1177750,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T20:16:20.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":215000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0000905148-25-001095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825001095/form4.xml","form_type":"4"}},{"id":1177749,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T20:13:48.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":140000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000905148-25-001094","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825001094/form4.xml","form_type":"4"}},{"id":1177751,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T20:12:12.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":65000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000905148-25-001093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000090514825001093/form4.xml","form_type":"4"}},{"id":1177748,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81060,"kind":"person","name":"Ahmad Qasim Iftikhar","position":1,"cik":"0001985801","reported_name":"Ahmad Qasim Iftikhar","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T20:09:52.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":215000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0000905148-25-001092","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825001092/form4.xml","form_type":"4"}},{"id":1177771,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T16:18:15.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":580000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":580000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":580000},"source":{"system":"sec-edgar","filing":"0000905148-25-001096","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000090514825001096/form4.xml","form_type":"4"}},{"id":1321828,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81060,"kind":"person","name":"Ahmad Qasim Iftikhar","position":1,"cik":"0001985801","reported_name":"Ahmad Qasim Iftikhar","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-26T13:50:34.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":31350,"price":0.847,"value":26553.45,"ownership":{"direct":true},"balance_after":31350,"source":{"system":"sec-edgar","filing":"0000905148-24-003414","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824003414/form4.xml","form_type":"4"}},{"id":1322975,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-23T23:53:56.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":10250,"price":0.8276,"value":8482.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades in prices ranging from $0.7861 to $0.90, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":84632,"source":{"system":"sec-edgar","filing":"0000905148-24-003410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824003410/form4.xml","form_type":"4"}},{"id":1322974,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-12-23T23:52:18.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.81,"value":9720.0,"ownership":{"direct":true},"balance_after":16938,"source":{"system":"sec-edgar","filing":"0000905148-24-003408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824003408/form4.xml","form_type":"4"}},{"id":1323020,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-23T18:56:14.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":0.8096,"value":10120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The actual purchase price is $0.809556 per share of Common Stock, which has been rounded due to systematic character limitations."}],"balance_after":49891,"source":{"system":"sec-edgar","filing":"0000905148-24-003412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000090514824003412/form4.xml","form_type":"4"}},{"id":1448145,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-07-27T01:22:20.000Z","date":"2024-07-26","kind":"sale","planned":false,"acquired":false,"shares":23478,"price":1.3113,"value":30786.7014,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":4354449,"source":{"system":"sec-edgar","filing":"0000950170-24-087061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024087061/ownership.xml","form_type":"4"}},{"id":1448144,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-07-27T01:22:20.000Z","date":"2024-07-25","kind":"sale","planned":false,"acquired":false,"shares":51522,"price":1.3264,"value":68338.7808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":4377927,"source":{"system":"sec-edgar","filing":"0000950170-24-087061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024087061/ownership.xml","form_type":"4"}},{"id":1487114,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":36755,"kind":"person","name":"Smith David V","position":1,"cik":"0001229447","reported_name":"Smith David V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:19:07.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001687","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001687/form4.xml","form_type":"4"}},{"id":1487112,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":39978,"kind":"person","name":"Hunter Heidi","position":1,"cik":"0001891841","reported_name":"Hunter Heidi","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:18:20.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001686","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001686/form4.xml","form_type":"4"}},{"id":1487113,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:17:32.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001685","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001685/form4.xml","form_type":"4"}},{"id":1487111,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78796,"kind":"person","name":"Glaub Kathleen Sereda","position":1,"cik":"0001619612","reported_name":"Glaub Kathleen Sereda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:16:03.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001684","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001684/form4.xml","form_type":"4"}},{"id":1487109,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:14:19.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001683","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001683/form4.xml","form_type":"4"}},{"id":1487110,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:12:22.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001682","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001682/form4.xml","form_type":"4"}},{"id":1517710,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-05-15T01:13:16.000Z","date":"2024-05-10","kind":"sale","planned":false,"acquired":false,"shares":658809,"price":1.2181,"value":802495.2429,"ownership":{"direct":true},"balance_after":4429449,"source":{"system":"sec-edgar","filing":"0000950170-24-059965","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024059965/ownership.xml","form_type":"4"}},{"id":1572653,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T20:24:57.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":280000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000905148-24-000969","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824000969/form4.xml","form_type":"4"}},{"id":1572651,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T20:23:03.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":185000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0000905148-24-000968","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824000968/form4.xml","form_type":"4"}},{"id":1572658,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T20:22:03.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":50000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000905148-24-000967","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000090514824000967/form4.xml","form_type":"4"}},{"id":1572650,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81060,"kind":"person","name":"Ahmad Qasim Iftikhar","position":1,"cik":"0001985801","reported_name":"Ahmad Qasim Iftikhar","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T20:18:04.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":280000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000905148-24-000966","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824000966/form4.xml","form_type":"4"}},{"id":1572714,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-18T16:27:32.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":750000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000905148-24-000970","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000090514824000970/form4.xml","form_type":"4"}},{"id":1646533,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-14T02:31:13.000Z","date":"2024-02-09","kind":"sale","planned":false,"acquired":false,"shares":658809,"price":1.5003,"value":988411.1427,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":5088258,"source":{"system":"sec-edgar","filing":"0001209191-24-003303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919124003303/doc4.xml","form_type":"4"}},{"id":1730424,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-11-24T22:37:11.000Z","date":"2023-11-22","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.035,"value":5175.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades in prices ranging from $1.03 to $1.04, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":11500,"source":{"system":"sec-edgar","filing":"0000905148-23-001527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000090514823001527/form4.xml","form_type":"4"}},{"id":1730423,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-11-24T22:37:11.000Z","date":"2023-11-21","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.99,"value":4950.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0000905148-23-001527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000090514823001527/form4.xml","form_type":"4"}},{"id":1737036,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T21:47:01.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":64238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":64238,"derivative":{"exercise_price":0.98,"expiration_date":"2033-11-15","underlying":"Common Stock","underlying_shares":64238},"source":{"system":"sec-edgar","filing":"0000905148-23-001485","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514823001485/form4.xml","form_type":"4"}},{"id":1807481,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":39978,"kind":"person","name":"Hunter Heidi","position":1,"cik":"0001891841","reported_name":"Hunter Heidi","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-15T22:02:13.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":64238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":64238,"derivative":{"exercise_price":1.83,"expiration_date":"2033-08-11","underlying":"Common Stock","underlying_shares":64238},"source":{"system":"sec-edgar","filing":"0001140361-23-039937","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039937/form4.xml","form_type":"4"}},{"id":1810031,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-12T01:24:23.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":0.125,"value":987654.25,"ownership":{"direct":false,"nature":"Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any."}],"balance_after":7901234,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":7901234},"source":{"system":"sec-edgar","filing":"0001140361-23-039346","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039346/form4.xml","form_type":"4"}},{"id":1810030,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-12T01:24:23.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":1.9,"value":15012344.6,"ownership":{"direct":false,"nature":"Lundbeckfond Invest A/S"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any."}],"balance_after":13950686,"source":{"system":"sec-edgar","filing":"0001140361-23-039346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039346/form4.xml","form_type":"4"}},{"id":1810033,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-12T01:22:20.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":0.125,"value":987654.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023)."}],"balance_after":7901234,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":7901234},"source":{"system":"sec-edgar","filing":"0001140361-23-039344","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039344/form4.xml","form_type":"4"}},{"id":1810032,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-12T01:22:20.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":1.9,"value":15012344.6,"ownership":{"direct":true},"balance_after":13950686,"source":{"system":"sec-edgar","filing":"0001140361-23-039344","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039344/form4.xml","form_type":"4"}},{"id":1810029,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-08-11T20:31:47.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":2469135,"price":2.025,"value":4999998.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement."}],"balance_after":2469135,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":2469135},"source":{"system":"sec-edgar","filing":"0001209191-23-045444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919123045444/doc4.xml","form_type":"4"}},{"id":1810028,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:31:47.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":2469135,"price":2.025,"value":4999998.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement."}],"balance_after":5707467,"source":{"system":"sec-edgar","filing":"0001209191-23-045444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919123045444/doc4.xml","form_type":"4"}},{"id":1810990,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":0.125,"value":394736.75,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":3157894},"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":1810989,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":1.9,"value":5999998.6,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":1812155,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-10T00:41:12.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":49382,"price":0.125,"value":6172.75,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023."}],"balance_after":49382,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":49382},"source":{"system":"sec-edgar","filing":"0001140361-23-038879","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123038879/form4.xml","form_type":"4"}},{"id":1812154,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-10T00:41:12.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":49382,"price":1.9,"value":93825.8,"ownership":{"direct":true},"balance_after":74382,"source":{"system":"sec-edgar","filing":"0001140361-23-038879","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123038879/form4.xml","form_type":"4"}},{"id":1812153,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-10T00:38:33.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":4938,"price":0.125,"value":617.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023."}],"balance_after":4938,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":4938},"source":{"system":"sec-edgar","filing":"0001140361-23-038877","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123038877/form4.xml","form_type":"4"}},{"id":1812152,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-08-10T00:38:33.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":4938,"price":1.9,"value":9382.2,"ownership":{"direct":true},"balance_after":4938,"source":{"system":"sec-edgar","filing":"0001140361-23-038877","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123038877/form4.xml","form_type":"4"}},{"id":1812199,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-09T20:43:49.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":37037,"price":0.125,"value":4629.625,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023."}],"balance_after":37037,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":37037},"source":{"system":"sec-edgar","filing":"0001140361-23-038881","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000114036123038881/form4.xml","form_type":"4"}},{"id":1812198,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-09T20:43:49.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":37037,"price":1.9,"value":70370.3,"ownership":{"direct":true},"balance_after":37391,"source":{"system":"sec-edgar","filing":"0001140361-23-038881","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000114036123038881/form4.xml","form_type":"4"}},{"id":1826987,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81060,"kind":"person","name":"Ahmad Qasim Iftikhar","position":1,"cik":"0001985801","reported_name":"Ahmad Qasim Iftikhar","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-19T20:20:18.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":288153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on July 17, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":288153,"derivative":{"exercise_price":1.86,"expiration_date":"2033-07-17","underlying":"Common Stock","underlying_shares":288153},"source":{"system":"sec-edgar","filing":"0001140361-23-035207","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123035207/form4.xml","form_type":"4"}},{"id":1857411,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":36755,"kind":"person","name":"Smith David V","position":1,"cik":"0001229447","reported_name":"Smith David V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T23:54:41.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":41533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":41533,"derivative":{"exercise_price":2.075,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":41533},"source":{"system":"sec-edgar","filing":"0001140361-23-029698","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123029698/form4.xml","form_type":"4"}},{"id":1857410,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T23:54:40.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":41533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":41533,"derivative":{"exercise_price":2.075,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":41533},"source":{"system":"sec-edgar","filing":"0001140361-23-029697","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123029697/form4.xml","form_type":"4"}},{"id":1857409,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T23:54:37.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":41533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":41533,"derivative":{"exercise_price":2.075,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":41533},"source":{"system":"sec-edgar","filing":"0001140361-23-029696","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123029696/form4.xml","form_type":"4"}},{"id":1857406,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78796,"kind":"person","name":"Glaub Kathleen Sereda","position":1,"cik":"0001619612","reported_name":"Glaub Kathleen Sereda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T23:54:34.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":41533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":41533,"derivative":{"exercise_price":2.075,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":41533},"source":{"system":"sec-edgar","filing":"0001140361-23-029695","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123029695/form4.xml","form_type":"4"}},{"id":1857407,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T23:54:32.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":41533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":41533,"derivative":{"exercise_price":2.075,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":41533},"source":{"system":"sec-edgar","filing":"0001140361-23-029694","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123029694/form4.xml","form_type":"4"}},{"id":1941854,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":115241,"kind":"person","name":"Al-Hajj Muhammad","position":1,"cik":"0001892300","reported_name":"Al-Hajj Muhammad","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T20:40:14.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":120000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001140361-23-013086","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123013086/form4.xml","form_type":"4"}},{"id":1941853,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T20:26:59.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":55000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001140361-23-013076","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123013076/form4.xml","form_type":"4"}},{"id":1941855,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T20:21:02.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":50000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-23-013072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000114036123013072/form4.xml","form_type":"4"}},{"id":1941898,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T16:34:51.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":500000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001140361-23-013081","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000114036123013081/form4.xml","form_type":"4"}},{"id":1941897,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":115245,"kind":"person","name":"Ehrnrooth Eva","position":1,"cik":"0001891333","reported_name":"Ehrnrooth Eva","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T16:13:40.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":120000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001140361-23-013063","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891333/000114036123013063/form4.xml","form_type":"4"}},{"id":1944772,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-20T21:35:52.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2.3207,"value":58017.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades in prices ranging from $2.18 to $2.46, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001140361-23-012596","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123012596/form4.xml","form_type":"4"}},{"id":2054891,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81061,"kind":"person","name":"Smith Devin Whittemore","position":1,"cik":"0001747818","reported_name":"Smith Devin Whittemore","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-13T21:49:09.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on January 12, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control."}],"balance_after":150000,"derivative":{"exercise_price":2.6,"expiration_date":"2033-01-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001567619-23-000919","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761923000919/doc1.xml","form_type":"4"}},{"id":2134876,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81062,"kind":"person","name":"Sullivan Amy","position":1,"cik":"0001887865","reported_name":"Sullivan Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-19T20:54:45.000Z","date":"2022-10-17","kind":"grant","acquired":true,"shares":288152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on 10/15/2023, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":288152,"derivative":{"exercise_price":2.55,"expiration_date":"2032-10-17","underlying":"Common Stock","underlying_shares":288152},"source":{"system":"sec-edgar","filing":"0001567619-22-018617","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922018617/doc1.xml","form_type":"4"}},{"id":2247795,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":48762,"kind":"person","name":"Burkavage Brian","position":1,"cik":"0001865633","reported_name":"Burkavage Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-02T22:25:10.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of these options vest on 5/31/2023, and 1/48th of these options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control."}],"balance_after":20000,"derivative":{"exercise_price":4.83,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-22-012194","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865633/000156761922012194/doc1.xml","form_type":"4"}},{"id":2251622,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T23:42:07.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":23885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":23885,"derivative":{"exercise_price":4.85,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":23885},"source":{"system":"sec-edgar","filing":"0001567619-22-011963","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922011963/doc1.xml","form_type":"4"}},{"id":2251621,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":36755,"kind":"person","name":"Smith David V","position":1,"cik":"0001229447","reported_name":"Smith David V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T23:40:54.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":23885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":23885,"derivative":{"exercise_price":4.85,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":23885},"source":{"system":"sec-edgar","filing":"0001567619-22-011962","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922011962/doc1.xml","form_type":"4"}},{"id":2251620,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78796,"kind":"person","name":"Glaub Kathleen Sereda","position":1,"cik":"0001619612","reported_name":"Glaub Kathleen Sereda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T23:39:07.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":23885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":23885,"derivative":{"exercise_price":4.85,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":23885},"source":{"system":"sec-edgar","filing":"0001567619-22-011961","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922011961/doc1.xml","form_type":"4"}},{"id":2251619,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":78795,"kind":"person","name":"Elling Christian E","position":1,"cik":"0001891306","reported_name":"Elling Christian E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T23:36:38.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":23885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":23885,"derivative":{"exercise_price":4.85,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":23885},"source":{"system":"sec-edgar","filing":"0001567619-22-011960","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922011960/doc1.xml","form_type":"4"}},{"id":2251616,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T23:34:23.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":23885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":23885,"derivative":{"exercise_price":4.85,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":23885},"source":{"system":"sec-edgar","filing":"0001567619-22-011959","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000156761922011959/doc1.xml","form_type":"4"}},{"id":2355358,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":36755,"kind":"person","name":"Smith David V","position":1,"cik":"0001229447","reported_name":"Smith David V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:30:24.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":28019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest monthly over three years from the vesting commencement date of March 1, 2022, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":28019,"derivative":{"exercise_price":6.89,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":28019},"source":{"system":"sec-edgar","filing":"0001140361-22-007684","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036122007684/form4.xml","form_type":"4"}},{"id":2515559,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":116796,"kind":"organization","name":"HBM Healthcare Investments (Cayman) Ltd.","position":1,"cik":"0001232258","reported_name":"HBM Healthcare Investments (Cayman) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:25.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":188168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365545},"source":{"system":"sec-edgar","filing":"0001104659-21-138088","document":"tm2131875-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000110465921138088/tm2131875-2_4seq1.xml","form_type":"4"}},{"id":2515558,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":116796,"kind":"organization","name":"HBM Healthcare Investments (Cayman) Ltd.","position":1,"cik":"0001232258","reported_name":"HBM Healthcare Investments (Cayman) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T21:16:25.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":325000,"price":14,"value":4550000.0,"ownership":{"direct":true},"balance_after":2690545,"source":{"system":"sec-edgar","filing":"0001104659-21-138088","document":"tm2131875-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000110465921138088/tm2131875-2_4seq1.xml","form_type":"4"}},{"id":2515557,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":116796,"kind":"organization","name":"HBM Healthcare Investments (Cayman) Ltd.","position":1,"cik":"0001232258","reported_name":"HBM Healthcare Investments (Cayman) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T21:16:25.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2365545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":2365545,"source":{"system":"sec-edgar","filing":"0001104659-21-138088","document":"tm2131875-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000110465921138088/tm2131875-2_4seq1.xml","form_type":"4"}},{"id":2515556,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":21325,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":267977},"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515555,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":63350,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":796059},"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515554,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":162500,"price":14,"value":2275000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":430477,"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515553,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":162500,"price":14,"value":2275000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":958559,"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515552,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":267977,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":267977,"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515551,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133580,"kind":"person","name":"Malier Vanessa","position":1,"cik":"0001891515","reported_name":"Malier Vanessa","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:21.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":796059,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any."}],"balance_after":796059,"source":{"system":"sec-edgar","filing":"0001140361-21-037655","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037655/form4.xml","form_type":"4"}},{"id":2515550,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":188168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365545},"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2515549,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":650000,"price":14,"value":9100000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":3015545,"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2515548,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2365545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":2365545,"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2515547,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133579,"kind":"person","name":"Andersson Claus A.","position":1,"cik":"0001890710","reported_name":"Andersson Claus A.","relationship":{"director":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:01.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":28225,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sunstone Life Science Ventures Fund III K/S (\"Sunstone Fund III\"). Sunstone LSV General Partner III ApS (\"Sunstone LSV GP III\") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":354830},"source":{"system":"sec-edgar","filing":"0001140361-21-037657","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037657/form4.xml","form_type":"4"}},{"id":2515546,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133579,"kind":"person","name":"Andersson Claus A.","position":1,"cik":"0001890710","reported_name":"Andersson Claus A.","relationship":{"director":true}}],"security":"Series B Preferred Stock","published_at":"2021-11-12T21:16:01.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":147881,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sunstone Life Science Ventures Fund III K/S (\"Sunstone Fund III\"). Sunstone LSV General Partner III ApS (\"Sunstone LSV GP III\") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1361660},"source":{"system":"sec-edgar","filing":"0001140361-21-037657","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037657/form4.xml","form_type":"4"}},{"id":2515545,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133579,"kind":"person","name":"Andersson Claus A.","position":1,"cik":"0001890710","reported_name":"Andersson Claus A.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:01.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":75000,"price":14,"value":1050000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sunstone Life Science Ventures Fund III K/S (\"Sunstone Fund III\"). Sunstone LSV General Partner III ApS (\"Sunstone LSV GP III\") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein."}],"balance_after":1791490,"source":{"system":"sec-edgar","filing":"0001140361-21-037657","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037657/form4.xml","form_type":"4"}},{"id":2515544,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133579,"kind":"person","name":"Andersson Claus A.","position":1,"cik":"0001890710","reported_name":"Andersson Claus A.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:01.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":354830,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sunstone Life Science Ventures Fund III K/S (\"Sunstone Fund III\"). Sunstone LSV General Partner III ApS (\"Sunstone LSV GP III\") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein."}],"balance_after":1716490,"source":{"system":"sec-edgar","filing":"0001140361-21-037657","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037657/form4.xml","form_type":"4"}},{"id":2515543,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":133579,"kind":"person","name":"Andersson Claus A.","position":1,"cik":"0001890710","reported_name":"Andersson Claus A.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:01.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":1361660,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sunstone Life Science Ventures Fund III K/S (\"Sunstone Fund III\"). Sunstone LSV General Partner III ApS (\"Sunstone LSV GP III\") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein."}],"balance_after":1361660,"source":{"system":"sec-edgar","filing":"0001140361-21-037657","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037657/form4.xml","form_type":"4"}},{"id":2515542,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":150534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1892434},"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515541,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":219595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2014161},"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515540,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":2142857,"price":14,"value":29999998.0,"ownership":{"direct":true},"balance_after":6049452,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515539,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":1892434,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":3906595,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515538,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2014161,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."}],"balance_after":2014161,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515537,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:15:36.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":188168,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365545},"source":{"system":"sec-edgar","filing":"0001140361-21-037652","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037652/form4.xml","form_type":"4"}},{"id":2515536,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:36.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":650000,"price":14,"value":9100000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3015545,"source":{"system":"sec-edgar","filing":"0001140361-21-037652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037652/form4.xml","form_type":"4"}},{"id":2515535,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:36.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2365545,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2365545,"source":{"system":"sec-edgar","filing":"0001140361-21-037652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037652/form4.xml","form_type":"4"}},{"id":2515600,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Class A Stock","published_at":"2021-11-12T16:15:54.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":26580,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Zocca Consulting ApS"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26580},"source":{"system":"sec-edgar","filing":"0001140361-21-037654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000114036121037654/form4.xml","form_type":"4"}},{"id":2515599,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":81064,"kind":"person","name":"Zocca Mai-Britt","position":1,"cik":"0001890736","reported_name":"Zocca Mai-Britt","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T16:15:54.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":26580,"ownership":{"direct":false,"nature":"Zocca Consulting ApS"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of his pecuniary interest therein."}],"balance_after":26580,"source":{"system":"sec-edgar","filing":"0001140361-21-037654","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890736/000114036121037654/form4.xml","form_type":"4"}},{"id":2518068,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C CONVERTIBLE PREFERRED STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":75267,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":946217},"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2518067,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B CONVERTIBLE PREFERRED STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":217107,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2006715},"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2518066,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":325000,"price":14,"value":4550000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":3277932,"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}}],"next_cursor":"2021-11-11T00:04:50.000000Z,2518066"}